Anthera Pharmaceuticals (ANTH) Shares are Down -5.11%

Anthera Pharmaceuticals (ANTH) : During the past 4 weeks, traders have been relatively bearish on Anthera Pharmaceuticals (ANTH), hence the stock is down -3.37% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.48% relative to the S&P 500. The 4-week change in the price of the stock is -3.57% and the stock has fallen -5.11% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 5.62% and the fifty day Moving Average is 6.54%. Anthera Pharmaceuticals, Inc. has dropped 14.9% during the last three month period . Year-to-Date the stock performance stands at -35.99%.

Anthera Pharmaceuticals (ANTH) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $14 and the lowest price target forecast is $9. The average forecast of all the analysts is $10.75 and the expected standard deviation is $2.22.


Anthera Pharmaceuticals (NASDAQ:ANTH): stock turned positive on Friday. Though the stock opened at $2.97, the bulls momentum made the stock top out at $3.0799 level for the day. The stock recorded a low of $2.88 and closed the trading day at $2.97, in the green by 0.68%. The total traded volume for the day was 540,719. The stock had closed at $2.95 in the previous days trading.

Anthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Companys primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Companys second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.